Showing 121 - 140 results of 18,226 for search 'significant ((((((shape decrease) OR (we decrease))) OR (greater decrease))) OR (a decrease))', query time: 0.57s Refine Results
  1. 121
  2. 122

    Achieving Improved Ion Swarm Shaping Based on Ion Leakage Control in Ion Mobility Spectrometry by Jiyao Wang (2121157)

    Published 2025
    “…Simulations and experiments demonstrate that precise voltage adjustments effectively minimize ion leakage, enhancing resolving power by 50% (reaching a maximum of 106), while the corresponding decrease in signal intensity follows the <i>I</i><sub>p</sub>–<i>R</i><sub>p</sub> linear relationship. …”
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  9. 129

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  10. 130

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  11. 131
  12. 132

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…In addition, genetic variation in age-related plasticity in exploration contributed to a decrease in the magnitude of genetic correlations during the adult stage. …”
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137

    Placebo test. by Le Zhu (1771669)

    Published 2025
    Subjects:
  18. 138
  19. 139
  20. 140